Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program

About This Program

This program aims to develop ICOS × PD-1 therapeutic bispecific antibody for colorectal cancer immunotherapy.

Rationale for our program:

Here, we propose a novel combination: ICOS × PD-1 therapeutic bispecific antibody, which could synergistically improve the anti-tumor response of tumor-reactive TILs.

ICOS × PD-1

Binding of PD-L1 to PD-1 on activated T cells inhibits expansion and survival of CD8-positive T cells, suppresses the immune system and leads to immune evasion. Blocking PD-1 abolishes T cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T cell-mediated tumor cell lysis, which may result in reduced tumor growth.

Inducible co-stimulator (ICOS) is the third member of the CD28/CTLA-4 family. As is well known, CD28 and CTLA-4, as one of the T cell-specific cell-surface receptors, are important regulators of the immune system. ICOS is a homodimeric protein and has only low levels of resting, naïve T cells. It binds specifically to its ligand (ICOS-L), also known as B7-related protein-1 (B7RP-1), which is expressed constitutively on B cells. ICOS/ICOSL axis has a dual effect and might participate in anti-tumour T cell response as well as a pro-tumour response due to its connection with regulatory T-cells (Tregs) suppressive activity.

Supporting Data

The following data support the rationale for the development of ICOS × PD-1 BiAbs with an improved therapeutic index more than anti-PD1 or anti-ICOS antibodies.

Colorectal Cancer

Ongoing Clinical Trials

Program Management

We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.

Fig.1 The timeline of Next-IOᵀᴹ programs. (Creative Biolabs Original)Fig.1 The timeline of Next-IOᵀᴹ programs.

Cooperation

Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop ICOS × PD-1 therapeutic bispecific antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.

Here are two ways for your choice, and please contact us for more details.

1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.

2) Become a licensed candidate for our programs.

With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chances to succeed. Look forward to cooperating with you in the near future.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.